🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the pathogen, according to scientists.

An International Health Concern

Cases of gonorrhoea are escalating worldwide, with estimates suggesting over 82 million infections each year. Particularly high rates are observed in Africa and nations within the WHO's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Secure Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization signifies a significant shift in the management of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Results and Worldwide Availability

Based on findings released by a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study included over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to license and sell the drug in many regions with limited resources.

Doctors treating patients have voiced positive views. Having a one-pill regimen of this kind is described as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea globally.